AIPBAND

An Integrated Platform for developing Brain cancer diagnostic techniques
Classificazione: 
internazionali
Programma: 
Horizon 2020
Call / Bando: 
Call MSCA-ITN-2017 An Integrated Platform for Developing Brain Cancer Diagnostic Techniques
Settore ERC: 
Life Sciences
Ruolo Unict: 
Partner
Durata del progetto in mesi: 
48
Data inizio: 
Lunedì, 1 Gennaio 2018
Data fine: 
Venerdì, 31 Dicembre 2021
Costo totale: 
€ 819.863,64
Quota Unict: 
€ 258.061,32
Coordinatore: 
University of Plymouth (United Kingdom)
Responsabile/i per Unict: 
Giuseppe Spoto
Dipartimenti e strutture coinvolte: 
Dipartimento di Scienze Chimiche
Altri partner: 

University College London (United Kingdom) - Imperial College of Science Technology and Medicine (United Kingdom) - Stockholms Universitet (Sweden) - Karolinska Institutet (Sweden) - Istituti Fisioterapici Ospitalieri (Italy) - Università degli Studi di Catania (Italy) - Scriba Nanotecnologie SRL (Italy) - Medical Trials Analysis Italy SRL (Italy) - The Hyve B.V. (Netherlands) - Stichting Katholieke Universiteit (Netherlands) - Katholieke Universiteit Leuven (Belgium)

ABSTRACT

The mission of AiPBAND is to train a new generation of entrepreneurial and innovative early-stage researchers (ESRs) in the early diagnosis of brain tumours using molecular biomarkers in the blood, meeting the medical and societal challenges of this emerging field. AiPBAND will focus on gliomas, a range of devastating and progressive brain tumours affecting around 25.000 people each year in Europe and responsible for the majority of deaths from primary brain tumours.